Market cap
$266 Mln
Revenue (TTM)
$48 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.1
-
Face value
--
-
Shares outstanding
53,228,300
6 Years Aggregate
CFO
$-1,032.99 Mln
EBITDA
$-1,045.46 Mln
Net Profit
$-1,425.19 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
2seventy bio (TSVT)
| 70.1 | 0.2 | 91.6 | 14.2 | -26.0 | -- | -- |
|
BSE Sensex*
| -12.6 | -4.3 | -4.6 | -10.3 | 5.7 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
2seventy bio (TSVT)
| -30.9 | -54.4 | -63.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
2seventy bio (TSVT)
|
5.0 | 266.1 | 48.4 | -4.1 | -122.7 | -1.9 | -- | 1.2 |
| 0.0 | 0.0 | 25.5 | -7.3 | -63.5 | -129.3 | -- | 0.0 | |
| 2.0 | 3.7 | 0.1 | -12.4 | -10,272.1 | -352.5 | -- | 9.9 |
Shareholding Pattern
View DetailsAbout 2seventy bio (TSVT)
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell... product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. Read more
-
President & Director
Mr. Nick Leschly
-
President & Director
Mr. Nick Leschly
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for 2seventy bio (TSVT)
What is the current share price of 2seventy bio Inc (TSVT) Today?
The share price of 2seventy bio Inc (TSVT) is $5.00 (NASDAQ) as of 22-May-2025 09:30 EDT. 2seventy bio Inc (TSVT) has given a return of -26.02% in the last 3 years.
What is the current PB & PE ratio of 2seventy bio Inc (TSVT)?
Since, TTM earnings of 2seventy bio Inc (TSVT) is negative, P/E ratio is not available.
The P/B ratio of 2seventy bio Inc (TSVT) is 1.24 times as on 22-May-2025, a 70 discount to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-2.69
|
0.73
|
|
2023
|
-1.01
|
0.86
|
|
2022
|
-1.41
|
1.16
|
|
2021
|
-2.09
|
1.70
|
|
2020
|
--
|
--
|
What is the 52 Week High and Low of 2seventy bio Inc (TSVT)?
The 52-week high and low of 2seventy bio Inc (TSVT) are Rs -- and Rs -- as of 10-Jun-2026.
What is the market cap of 2seventy bio Inc (TSVT)?
2seventy bio Inc (TSVT) has a market capitalisation of $ 266 Mln as on 22-May-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in 2seventy bio Inc (TSVT)?
Before investing in 2seventy bio Inc (TSVT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.